Detalles de la búsqueda
1.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Int J Clin Oncol
; 28(1): 79-88, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36414827
2.
A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).
Cancer
; 126(16): 3648-3656, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32484914
3.
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Gastric Cancer
; 22(2): 344-354, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30506519
4.
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Int J Clin Oncol
; 24(10): 1223-1230, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31144145
5.
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Cancer Sci
; 109(8): 2532-2538, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29807396
6.
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 16(16): 1630-8, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26522337
7.
[Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function].
Gan To Kagaku Ryoho
; 41(13): 2587-90, 2014 Dec.
Artículo
en Japonés
| MEDLINE | ID: mdl-25596053
8.
[Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy].
Gan To Kagaku Ryoho
; 39(6): 927-32, 2012 Jun.
Artículo
en Japonés
| MEDLINE | ID: mdl-22705687
9.
Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Clin Rheumatol
; 41(9): 2803-2808, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35399148
10.
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
J Clin Oncol
; 40(3): 231-241, 2022 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34726958
11.
Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.
Cancers (Basel)
; 14(24)2022 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36551721
12.
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Jpn J Clin Oncol
; 41(8): 948-52, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21715363
13.
Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab.
Target Oncol
; 16(2): 237-248, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33475927
14.
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(6): 904-909, 2021 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33734289
15.
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
JAMA Oncol
; 6(12): 1931-1938, 2020 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33057591
16.
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
J Clin Oncol
; 38(8): 793-803, 2020 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31880966
17.
Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
Anticancer Res
; 39(3): 1463-1468, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30842183
18.
Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer.
Cancer Res
; 65(21): 9623-7, 2005 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16266979
19.
Prevalence, Concomitance, and Distribution of Ossification of the Spinal Ligaments: Results of Whole Spine CT Scans in 1500 Japanese Patients.
Spine (Phila Pa 1976)
; 41(21): 1668-1676, 2016 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27120057
20.
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
J Clin Oncol
; 34(27): 3248-57, 2016 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27022112